Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
Early data with the RIPTAC HLD-0915 look competitive.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
AstraZeneca ended a tie-up with Asher, and then set off on its own.
